– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...

CurePSP hosted a congressional briefing this month in partnership with Representatives Subramanyam (D-VA) and Bilirakis (R-FL), bringing together lawmakers, scientists and people affected by ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Mission MSA is proud to announce its 2026 designated MSA Centers of Excellence (COE), a prestigious network of clinical institutions ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Lundbeck Advances Parkinson's Research With New Phase 1B Data At AD/PDTM 2026. Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented ...

A study by NIMHANS warns that atypical Parkinsonism, a faster and often misdiagnosed form of Parkinson’s Disease, is ...

A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

Explore the promising early results of PRI-101, a new treatment for Parkinson's disease aimed at targeting neurodegeneration.

ASX-listed healthcare companies are increasingly teaming up with universities to fast-track new therapies, combining academic ...